drugset / Trial / NCT04434001

ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery

NCT04434001

Phase 2 Terminated 40 enrolled IRCCS Policlinico S. Donato
RandomizedParallel-groupSingle-blindTreatment

Summary

In pediatric patients (newborns and infants weighing less than 10 kg) undergoing cardiac surgery with extracorporeal circulation postoperative bleeding represents a known complication with a significant impact on outcome. Fresh frozen plasma (FFP) for bleeding management is associated, particularly in this kind of patients, to volume overload and a significative increase of Transfusion Related Acute Lung Injury (TRALI), further worsening the postoperative outcome. In the adult patient FFP employment could be almost completely canceled by administration of concentrated hemostatic components - the fibrinogen concentrate and prothrombin complex concentrate (PCC). We designed this phase II pilot study to establish whether an analogous strategy, modified accordingly to pediatric physiology, could be safely and successfully applied in newborns and infants.

Timeline

Start
2020-02-27
Primary completion
2021-05-31
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fibrinogen Concentrate Human Protein / enzyme biologic 30 mg/kg
Comparator Fresh Frozen Plasma Protein / enzyme biologic 10 ml
Comparator Fresh Frozen Plasma Protein / enzyme biologic 20 ml
Subject Prothrombin Complex Concentrate Protein / enzyme biologic 20 mg/kg